| Autor: |
TAKASHI YOSHIOKA, MASANOBU TAKAHASHI, YASUHIRO SAKAMOTO, AKIRA OKITA, TADAHISA FUKUI, YASUKO MURAKAWA, YOSHIAKI SHINDO, HIROO IMAI, HISATSUGU OHORI, HIDEKAZU SHIROTA, NATSUKO CHIBA, YURIKO (ITO) SASAHARA, TAKASHI NOMURA, NORIMASA FUKUSHIMA, TAKUHIRO YAMAGUCHI, HIDEKI SHIMODAIRA, CHIKASHI ISHIOKA |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Anticancer research. 42(4) |
| ISSN: |
1791-7530 |
| Popis: |
This phase II study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1.This single-arm, open-label, multicenter, phase II study was conducted by Tohoku Clinical Oncology Research and Education Society (T-CORE) in Japan. Patients aged ≥20 years with advanced HER2-negative gastric cancer that was refractory to S-1 were enrolled. Patients received 80 mg/mIn total, 21 patients were enrolled from seven hospitals. The median patient age was 63 years. Nineteen patients received the protocol treatment. Median PFS was 3.7 months [90% confidence interval (CI)=2.7-5.6 months], which did not reach the predefined threshold of 4.0 months. ORR was 5.9% (95%CI=0.0-17.1%). Median OS was 11.9 months (95% CI 6.3-19.4 months). Febrile neutropenia was observed in 5.3% of patients. The most frequently observed grade 3 non-hematologic toxicities were nausea (15.8%) and hyponatremia (15.8%).The addition of a fluoropyrimidine to a platinum agent after adjuvant therapy is not suitable for gastric cancer. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
